NCT05998642 - Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2024

Primary Completion Date

May 31, 2028

Study Completion Date

December 31, 2028

Conditions

Non-hodgkin Lymphoma

Interventions

DRUG

Methotrexate

3.5mg/m2 IV

DRUG

Rituximab (where available)

375mg/m2 / 1400mg IV or SC

DRUG

Ibrutinib

Dose and schedule assigned at enrollment

Trial Locations (7)

T2N 5G2

RECRUITING

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

V5Z 4E6

RECRUITING

BCCA - Vancouver, Vancouver

L8V 5C2

RECRUITING

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

RECRUITING

University Health Network, Toronto

H4A 3J1

RECRUITING

The Research Institute of the McGill University, Montreal

G1J 1Z4

RECRUITING

CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec

All Listed Sponsors

collaborator

Janssen Inc.

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK